Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

BACH1 is thought to be a key regulator of cellular responses, oxidative stress, and inflammation in multiple disease states, making it a promising therapeutic target.

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

FANCJ, also known as BACH1 or BRIP1, was identified as a direct BRCA1-BRCT interacting protein and functions in DNA repair and checkpoint control. Bi-allelic inheritance of mutations in FANCJ ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other chronic conditions.

DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...